Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = radioimmune therapy

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
13 pages, 1936 KiB  
Article
Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma
by Sarah McCollum, Austen Kalivas, Matthew Kirkham, Kaden Kunz, Jeffrey Okojie, Adriene Pavek and Jared Barrott
Pharmaceuticals 2022, 15(6), 650; https://doi.org/10.3390/ph15060650 - 24 May 2022
Cited by 4 | Viewed by 3229
Abstract
Synovial sarcoma (SS) is a pediatric muscle cancer that primarily affects adolescents and young adults and has few treatment options. Complicating the treatment of synovial sarcoma is the low mutational burden of SS. Inflammatory pathways have been identified as being upregulated in some [...] Read more.
Synovial sarcoma (SS) is a pediatric muscle cancer that primarily affects adolescents and young adults and has few treatment options. Complicating the treatment of synovial sarcoma is the low mutational burden of SS. Inflammatory pathways have been identified as being upregulated in some SS, leading to the discovery of upregulated oncostatin M receptor (OSMR). It was found that OSMR is upregulated in SS by RNAseq analysis and quantitative PCR, highlighting its potential in the treatment of SS. Also, OSMR is upregulated in mouse models for synovial sarcoma as demonstrated by western blot and immunohistochemistry, and the protein is present in both primary and metastatic sites of disease. Using a radioimmune therapy drug model, targeted therapy was synthesized for use in OSMR expressing SS and it was demonstrated that this drug is stable, while capable of efficient OSMR binding and isotope capture. Finally, this antibody conjugate exhibited ideal pharmacokinetics and targeted sites of disease in our mouse model and was taken up in both primary and metastatic diseased tissue. This suggests OSMR as an ideal target for therapy and this radioimmune therapy provides a novel treatment option for a disease with few therapy choices. Full article
(This article belongs to the Section Radiopharmaceutical Sciences)
Show Figures

Figure 1

Back to TopTop